Altamira Therapeutics Ltd

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Testing further confirms Bentrio's broad protection against various types of airborne viruses Demonstrates significant reductions in viral load for preventive and mitigative treatment after 4 days vs. saline controls HAMILTON, BERMUDA / ACCESSWIRE / June 8, 2022 / Altamira Therapeutics Ltd.

Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that Bentrio™ has been approved by the Ministry of Health of Indonesia and is, therefore, cleared for commercialization in that country.

Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia

HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that Bentrio™ has been approved by the Philippines' Food and Drug Administration (FDA) and is now cleared for commercialization in that country of 115 million people.

Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray

Altamira Therapeutics Ltd (NASDAQ: CYTO) announced topline data from its clinical trial with Bentrio nasal spray in house dust mite (HDM) allergic rhinitis. The HDM challenge trial demonstrated a statistically significant reduction of nasal symptoms vs.

Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study

Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safety HAMILTON, BERMUDA / ACCESSWIRE / May 20, 2022 / Altamira Therapeutics Ltd.

Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study

HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it is scheduled to present virtually at the H.C.

Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference

Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today issued a Letter to Shareholders providing highlights of the Company's recent achievements and its 2022 outlook.

Altamira Therapeutics Issues Shareholder Letter

Extending clinical study will complement the ongoing trial in Bulgaria Reaffirms it expects to complete the study in 3Q-22 subject to sufficient COVID-19 incidence HAMILTON, BERMUDA / ACCESSWIRE / May 5, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received regulatory approval from the North Macedonia Ministry of Health to extend the COVAMID clinical investigation of its Bentrio™ nasal spray in patients with acute COVID-19 into the Republic of North Macedonia.

Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia

HAMILTON, BERMUDA / ACCESSWIRE / April 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that that it has reached the midpoint for enrollment in its COVAMID clinical investigation of its Bentrio™ nasal spray in patients with acute COVID-19.

Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19

Altamira Therapeutics Ltd. (CYTO) CEO Thomas Meyer on Q4 2021 Results - Earnings Call Transcript

Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern. Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliver Established new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasal spray and successfully established distribution partners covering more than 20 countries so far.

Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results

Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are trading higher Monday after the company announced a peer-reviewed publication on positive in vitro data with its Bentrio drug-free nasal spray against the SARS-CoV-2 delta variant. The International Journal of Molecular Sciences .

Why Altamira Therapeutics Stock Is Soaring

Study Confirms in vitro Efficacy / Safety of Bentrio(TM) for Delta Variant Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls over 4 days, reaching a maximum reduction of 99% with the wild-type SARS-CoV-2 variant and more than 83% with the Delta variant Bentrio™ administered 24 hours after infection saw the viral titer decrease by approximately 12-folds, and 3-folds on Day 4 Bentrio™ recently showed positive in vitro test results also against the Omicron variant in separate study HAMILTON, BERMUDA / ACCESSWIRE / April 11, 2022 / Altamira Therapeutics Ltd.

Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant

HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold an investor call on Tuesday, April 12, 2022, 8:00 a.m.

Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET

HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced completion of patient enrollment in its Bentrio™ trial in house dust mite ("HDM") allergic rhinitis.

Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio

Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are surging after announcing preclinical efficacy data from testing its Bentrio nasal spray against the omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection against airborne viruses and allergens.

Why Are Altamira Therapeutics Shares Gaining Today?

Humanigen

Kala Pharmaceuticals

Arcadia Biosciences

Nasdaq Penny Stocks List For March The post 4 Nasdaq Penny Stocks To Buy For Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Nasdaq Penny Stocks To Buy For Under $5

HAMILTON, BERMUDA / ACCESSWIRE / March 11, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus.

Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant

HAMILTON, BERMUDA / ACCESSWIRE / March 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of Bentrio™ in COVID-19 patients (the "COVAMID" study).

Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19

75 patients randomized in Part B of study to receive either intranasal betahistine or placebo Top-line results from the trial expected to be announced in Q2-2022 HAMILTON, BERMUDA / ACCESSWIRE / February 14, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced completion of patient enrollment in Part B of the Phase 2 ‘TRAVERS' clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo.

Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo

HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the geographic scope of its existing marketing and distribution agreement (the "Agreement") for Bentrio™ with Wellesta Holding Pte Ltd ("Wellesta") has been expanded.

Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets

HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an agreement for the marketing and distribution of Bentrio™ (the "Agreement"), its nasal spray for protection against airborne viruses and allergens, with Avernus Pharma Ltd.

Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries

Dedicated unit to support Altamira's activities in consumer health products OTC Consumer Health to be led by experienced marketing strategist, Jean Lachance HAMILTON, BERMUDA / ACCESSWIRE / February 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio™, its nasal spray for the protection against airborne viruses and allergens.

Altamira Therapeutics Establishes OTC Consumer Health Business Unit

The Medical Device Authority of Malaysia has approved Altamira Therapeutics Ltd's (NASDAQ: CYTO) Bentrio. "We are very pleased with the swift 'go-to-market' progress in Malaysia and Singapore," commented Thomas Meyer, Founder, Chairman, and CEO.

Altamira's Bentrio Nasal Spray Approved In Malaysia

HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics announced today that Bentrio™ has been approved by the Medical Device Authority of Malaysia and is, therefore, cleared for commercialization in that country.

News for Altamira Therapeutics Ltd Stock (CYTO)